
    
      This was a phase 3, open-label, baseline-controlled, multicenter study. The study consisted
      of 3 periods: Pretreatment period: for a maximum of 28 days before baseline, including
      screening, washout (if applicable) and baseline.

      Efficacy treatment period: beginning the day after baseline and continuing to week 24.
      Long-term safety period: beginning after week 24 and continuing to week 52 (end of study
      [EOS]), or to the end of treatment (EOT).
    
  